Alain van Mil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alain van Mil has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Joost Petrus Gerardus Sluijter
Department of Cardiology and Experimental Cardiology Laboratory, Division of Heart & Lungs, University Medical Centre Utrecht, Utrecht, the Netherlands
6 shared publications Inge Dokter
Experimental Cardiology Laboratory, department of Cardiology, division of Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands; Regenerative Medicine Center Utrecht, Circulatory Health Research Center, University Medical Center Utrecht, University Utrecht, the Netherlands
5 shared publicationsPieter A. Doevendans
Netherlands Heart Institute (NLHI), Utrecht, the Netherlands; Central Military Hospital (CMH), Utrecht, the Netherlands
5 shared publicationsJiabin Qin
Department of Cardiology, University Medical Center Utrecht, Laboratory of Experimental Cardiology, Regenerative Medicine Center Utrecht, Circulatory Health Research Center, University Utrecht, Utrecht, the Netherlands
4 shared publicationsJoost P. G. Sluijter
Department of Cardiology, Experimental Cardiology Laboratory, Circulatory Health Research Center, Regenerative Medicine Center Utrecht, University Utrecht, University Medical Center Utrecht, Uppsalalaan 8, Utrecht, 3584 CT, The Netherlands
4 shared publications- Jos Malda
University Medical Center Utrecht
4 shared publications
Latest Publications
- Open Access
Increased Nuclear Susceptibility to Mechanical Stress in Phospholamban R14del Cardiomyopathy: A New Perspective on Disease Heterogeneity
Background: Clinical presentation of phospholamban (PLN) R14del cardiomyopathy is highly variable, from asymptomatic carriers to rapidly progressing heart failure. which cannot be fully explained by its known disturbance of sarcoplasmic reticulum calcium handling. Nuclear calcium signalling, shaped by sarcoplasmic reticulum calcium release, plays a key role in regulating gene expression and the cellular response to mechanical stress. However, how the R14del variant affects nuclear signalling under mechanical loading remains unclear. Objective: To uncover the impact of the PLN R14del variation on mechanosensing, nuclear calcium handling and its link to the variable clinical representation of this cardiomyopathy. Methods: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the PLN R14del variant, an isogenic control, and wildtype control were subjected to mechanical stimulation by cyclic stretch or cultured on substrates with physiological (10-20 kPa) and pathological (65-85 kPa) stiffness. Nuclear morphology, cytoskeletal organisation and nuclear body formation were assessed via immunofluorescence. Traction force microscopy was used to assess mechanical stress and force generation. Cardiac tissues from PLN R14del cardiomyopathy patients, dilated cardiomyopathy patients, and healthy controls were analysed under mechanical loading (at left ventricular assist device implantation) and unloading (at heart transplantation). Living myocardial slices from a PLN R14del patient were maintained under overloading or physiological loading conditions. Results: PLN R14del hiPSC-CMs showed impaired nuclear calcium handling and, under mechanical stress, exhibited impaired mechanotransduction and elevated nuclear bodies. A strain-avoidance response was triggered but failed to prevent apoptosis. Nuclear abnormalities were confirmed in patient myocardial slices and cardiac biopsies which normalized upon relative mechanical unloading. Conclusion: PLN R14del increases nuclear susceptibility to mechanical stress, linking nuclear dysfunction to new disease insights and highlighting potential for mechanobiology-based therapeutic interventions. Condensed PLN R14del cardiomyopathy presents with highly variable clinical severity, which cannot be fully explained by its known disturbance of sarcoplasmic reticulum calcium handling. We investigated whether the R14del variant impairs nuclear calcium signalling and mechanosensing, thereby contributing to disease heterogeneity. Using PLN R14del, isogenic control, and wildtype hiPSC-CMs subjected to cyclic stretch and substrates of physiological and pathological stiffness, we demonstrate that PLN R14del cardiomyocytes exhibit impaired nuclear calcium handling, elevated nuclear damage, disrupted cytoskeletal organisation, and failed mechanotransduction under mechanical stress. Although a strain-avoidance response was triggered, it was insufficient to prevent apoptosis. These findings were confirmed in living myocardial slices and cardiac biopsies from PLN R14del patients, where nuclear abnormalities were most pronounced under mechanical loading and reversed upon unloading. Together, these data establish increased nuclear susceptibility to mechanical stress as a novel pathological feature of PLN R14del cardiomyopathy, offering new insight into disease heterogeneity and highlighting mechanobiology-based therapeutic opportunities.
Open AccessIncreased Nuclear Susceptibility to Mechanical Stress in Phospholamban R14del Cardiomyopathy: A New Perspective on Disease Heterogeneity
Background: Clinical presentation of phospholamban (PLN) R14del cardiomyopathy is highly variable, from asymptomatic carriers to rapidly progressing heart failure. which cannot be fully explained by its known disturbance of sarcoplasmic reticulum calcium handling. Nuclear calcium signalling, shaped by sarcoplasmic reticulum calcium release, plays a key role in regulating gene expression and the cellular response to mechanical stress. However, how the R14del variant affects nuclear signalling under mechanical loading remains unclear. Objective: To uncover the impact of the PLN R14del variation on mechanosensing, nuclear calcium handling and its link to the variable clinical representation of this cardiomyopathy. Methods: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the PLN R14del variant, an isogenic control, and wildtype control were subjected to mechanical stimulation by cyclic stretch or cultured on substrates with physiological (10-20 kPa) and pathological (65-85 kPa) stiffness. Nuclear morphology, cytoskeletal organisation and nuclear body formation were assessed via immunofluorescence. Traction force microscopy was used to assess mechanical stress and force generation. Cardiac tissues from PLN R14del cardiomyopathy patients, dilated cardiomyopathy patients, and healthy controls were analysed under mechanical loading (at left ventricular assist device implantation) and unloading (at heart transplantation). Living myocardial slices from a PLN R14del patient were maintained under overloading or physiological loading conditions. Results: PLN R14del hiPSC-CMs showed impaired nuclear calcium handling and, under mechanical stress, exhibited impaired mechanotransduction and elevated nuclear bodies. A strain-avoidance response was triggered but failed to prevent apoptosis. Nuclear abnormalities were confirmed in patient myocardial slices and cardiac biopsies which normalized upon relative mechanical unloading. Conclusion: PLN R14del increases nuclear susceptibility to mechanical stress, linking nuclear dysfunction to new disease insights and highlighting potential for mechanobiology-based therapeutic interventions. Condensed PLN R14del cardiomyopathy presents with highly variable clinical severity, which cannot be fully explained by its known disturbance of sarcoplasmic reticulum calcium handling. We investigated whether the R14del variant impairs nuclear calcium signalling and mechanosensing, thereby contributing to disease heterogeneity. Using PLN R14del, isogenic control, and wildtype hiPSC-CMs subjected to cyclic stretch and substrates of physiological and pathological stiffness, we demonstrate that PLN R14del cardiomyocytes exhibit impaired nuclear calcium handling, elevated nuclear damage, disrupted cytoskeletal organisation, and failed mechanotransduction under mechanical stress. Although a strain-avoidance response was triggered, it was insufficient to prevent apoptosis. These findings were confirmed in living myocardial slices and cardiac biopsies from PLN R14del patients, where nuclear abnormalities were most pronounced under mechanical loading and reversed upon unloading. Together, these data establish increased nuclear susceptibility to mechanical stress as a novel pathological feature of PLN R14del cardiomyopathy, offering new insight into disease heterogeneity and highlighting mechanobiology-based therapeutic opportunities.
- Open Access
- 4 September 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40, 103647
A study on extracellular and cellular composition to advance towards the rational design of contractile human myocardium
- 4 September 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40, 103647
Open AccessA study on extracellular and cellular composition to advance towards the rational design of contractile human myocardium
- 11 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis
Background and Aims: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive cause of heart failure, especially in the ageing society, but cellular biological mechanism studies are limited by the lack of robust animal models. Vitronectin (VTN), an extracellular matrix (ECM) glycoprotein enriched in amyloid deposits, may contribute to amyloidogenesis, yet its pathogenic role in ATTR-CM remains undefined. Methods: Humanized knock-in mice expressing either wild-type (hTTRWT) or V142I mutant transthyretin (hTTRV142I) were generated. Amyloid burden, cardiac structure, and function were assessed by Congo red staining, electron microscopy, echocardiography, and cardiac magnetic resonance. The functional role of VTN and integrin signalling was studied using genetic silencing and pharmacological intervention with low-dose cilengitide. Results: Both hTTRWT and hTTRV142I mice developed age-dependent cardiac amyloidosis with diastolic dysfunction and reduced survival, especially in the hTTRV142I strain. VTN co-localized with TTR fibrils, promoted fibril aggregation, reduced amyloid burden upon its knockdown, and preserved cardiac function. Mechanistically, TTR amyloid suppressed integrin αvβ3/FAK/Akt signalling, leading to marked mitochondrial dysregulation characterized by excessive fission, enhanced mitophagy, and impaired oxidative phosphorylation. Restoration of αvβ3 signalling with cilengitide normalized mitochondrial dynamics, improved bioenergetics, and ameliorated diastolic dysfunction despite persistent amyloid stress. Conclusions: Two reproducible ATTR-CM models that recapitulate the steadily progressive course of human disease were established. Furthermore, VTN actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid–ECM interactions to mitochondrial dysfunction. Therefore, modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression.
- 11 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis
Background and Aims: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive cause of heart failure, especially in the ageing society, but cellular biological mechanism studies are limited by the lack of robust animal models. Vitronectin (VTN), an extracellular matrix (ECM) glycoprotein enriched in amyloid deposits, may contribute to amyloidogenesis, yet its pathogenic role in ATTR-CM remains undefined. Methods: Humanized knock-in mice expressing either wild-type (hTTRWT) or V142I mutant transthyretin (hTTRV142I) were generated. Amyloid burden, cardiac structure, and function were assessed by Congo red staining, electron microscopy, echocardiography, and cardiac magnetic resonance. The functional role of VTN and integrin signalling was studied using genetic silencing and pharmacological intervention with low-dose cilengitide. Results: Both hTTRWT and hTTRV142I mice developed age-dependent cardiac amyloidosis with diastolic dysfunction and reduced survival, especially in the hTTRV142I strain. VTN co-localized with TTR fibrils, promoted fibril aggregation, reduced amyloid burden upon its knockdown, and preserved cardiac function. Mechanistically, TTR amyloid suppressed integrin αvβ3/FAK/Akt signalling, leading to marked mitochondrial dysregulation characterized by excessive fission, enhanced mitophagy, and impaired oxidative phosphorylation. Restoration of αvβ3 signalling with cilengitide normalized mitochondrial dynamics, improved bioenergetics, and ameliorated diastolic dysfunction despite persistent amyloid stress. Conclusions: Two reproducible ATTR-CM models that recapitulate the steadily progressive course of human disease were established. Furthermore, VTN actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid–ECM interactions to mitochondrial dysfunction. Therefore, modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression.
- Open Access
- 19 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119238
Photoporation enables non-viral delivery of prime editing RNP complexes into human iPSC-derived cardiomyocytes for cardiac genome correction
- 19 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119238
Open AccessPhotoporation enables non-viral delivery of prime editing RNP complexes into human iPSC-derived cardiomyocytes for cardiac genome correction
- Open Access
- 28 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126622
LAH5-mediated delivery of prime editor ribonucleoprotein complexes for genome editing
- 28 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126622
Open AccessLAH5-mediated delivery of prime editor ribonucleoprotein complexes for genome editing
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 1997-2013
In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential
Amyloid light chain (AL) and transthyretin amyloidosis (ATTR)-induced cardiomyopathy are life-threatening protein misfolding disorders characterized by amyloid fibril deposition in the heart, which significantly impairs cardiac function. The lack of representative disease models has impeded progress in understanding the underlying mechanisms and hindered the discovery and development of specific biomarkers and effective therapies. To address this, researchers have developed various cell and animal models to recapitulate these diseases. In AL amyloidosis, cell and mouse models have highlighted the toxic effects of both soluble light chains (LCs) and LC-derived amyloid fibrils, such as lysosomal dysfunction, endoplasmic reticulum stress, and oxidative stress. Transgenic mouse models, particularly those without the mouse heavy chain and with amyloid seeds addition, have successfully replicated systemic AL amyloidosis, with clear effects on the heart. For ATTR amyloidosis, acid-induced transthyretin (TTR) fibrils induce cellular dysfunction, such as increased intracellular reactive oxygen species (ROS) level, disorganized sarcomere, and prolonged calcium handling in 2D cell models. Transgenic mouse models expressing human WT or variant TTR have offered insights into the development of amyloid cardiomyopathy, but challenges persist in fully replicating the human phenotype. This review offers a comprehensive overview of the significant advancements, challenges, and future perspectives in the development of various cell and animal models for studying AL and ATTR amyloidosis-induced cardiomyopathy, thereby providing valuable insights into disease pathophysiology, early accurate biomarkers identification, and development of novel therapies.
- 1 September 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 1997-2013
Open AccessIn vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential
Amyloid light chain (AL) and transthyretin amyloidosis (ATTR)-induced cardiomyopathy are life-threatening protein misfolding disorders characterized by amyloid fibril deposition in the heart, which significantly impairs cardiac function. The lack of representative disease models has impeded progress in understanding the underlying mechanisms and hindered the discovery and development of specific biomarkers and effective therapies. To address this, researchers have developed various cell and animal models to recapitulate these diseases. In AL amyloidosis, cell and mouse models have highlighted the toxic effects of both soluble light chains (LCs) and LC-derived amyloid fibrils, such as lysosomal dysfunction, endoplasmic reticulum stress, and oxidative stress. Transgenic mouse models, particularly those without the mouse heavy chain and with amyloid seeds addition, have successfully replicated systemic AL amyloidosis, with clear effects on the heart. For ATTR amyloidosis, acid-induced transthyretin (TTR) fibrils induce cellular dysfunction, such as increased intracellular reactive oxygen species (ROS) level, disorganized sarcomere, and prolonged calcium handling in 2D cell models. Transgenic mouse models expressing human WT or variant TTR have offered insights into the development of amyloid cardiomyopathy, but challenges persist in fully replicating the human phenotype. This review offers a comprehensive overview of the significant advancements, challenges, and future perspectives in the development of various cell and animal models for studying AL and ATTR amyloidosis-induced cardiomyopathy, thereby providing valuable insights into disease pathophysiology, early accurate biomarkers identification, and development of novel therapies.
- Open Access
- 24 June 2024
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 12 (15) , 3866-3881
Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs
Cardiac tissue engineering (cTE) has already advanced towards the first clinical trials, investigating safety and feasibility of cTE construct transplantation in failing hearts. However, the lack of well-established preservation methods poses a hindrance to further scalability, commercialization, and transportation, thereby reducing their clinical implementation. In this study, hypothermic preservation (4 °C) and two methods for cryopreservation (i.e., a slow and fast cooling approach to −196 °C and −150 °C, respectively) were investigated as potential solutions to extend the cTE construct implantation window. The cTE model used consisted of human induced pluripotent stem cell-derived cardiomyocytes and human cardiac fibroblasts embedded in a natural-derived hydrogel and supported by a polymeric melt electrowritten hexagonal scaffold. Constructs, composed of cardiomyocytes of different maturity, were preserved for three days, using several commercially available preservation protocols and solutions. Cardiomyocyte viability, function (beat rate and calcium handling), and metabolic activity were investigated after rewarming. Our observations show that cardiomyocytes’ age did not influence post-rewarming viability, however, it influenced construct function. Hypothermic preservation with HypoThermosol® ensured cardiomyocyte viability and function. Furthermore, fast freezing outperformed slow freezing, but both viability and function were severely reduced after rewarming. In conclusion, whereas long-term preservation remains a challenge, hypothermic preservation with HypoThermosol® represents a promising solution for cTE construct short-term preservation and potential transportation, aiding in off-the-shelf availability, ultimately increasing their clinical applicability.
- 24 June 2024
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 12 (15) , 3866-3881
Open AccessHypothermic and cryogenic preservation of cardiac tissue-engineered constructs
Cardiac tissue engineering (cTE) has already advanced towards the first clinical trials, investigating safety and feasibility of cTE construct transplantation in failing hearts. However, the lack of well-established preservation methods poses a hindrance to further scalability, commercialization, and transportation, thereby reducing their clinical implementation. In this study, hypothermic preservation (4 °C) and two methods for cryopreservation (i.e., a slow and fast cooling approach to −196 °C and −150 °C, respectively) were investigated as potential solutions to extend the cTE construct implantation window. The cTE model used consisted of human induced pluripotent stem cell-derived cardiomyocytes and human cardiac fibroblasts embedded in a natural-derived hydrogel and supported by a polymeric melt electrowritten hexagonal scaffold. Constructs, composed of cardiomyocytes of different maturity, were preserved for three days, using several commercially available preservation protocols and solutions. Cardiomyocyte viability, function (beat rate and calcium handling), and metabolic activity were investigated after rewarming. Our observations show that cardiomyocytes’ age did not influence post-rewarming viability, however, it influenced construct function. Hypothermic preservation with HypoThermosol® ensured cardiomyocyte viability and function. Furthermore, fast freezing outperformed slow freezing, but both viability and function were severely reduced after rewarming. In conclusion, whereas long-term preservation remains a challenge, hypothermic preservation with HypoThermosol® represents a promising solution for cTE construct short-term preservation and potential transportation, aiding in off-the-shelf availability, ultimately increasing their clinical applicability.
- Open Access
- 30 June 2023
- Published by IOP Publishing in Biofabrication
- Vol. 15 (3) , 035025
Convergence of melt electrowriting and extrusion-based bioprinting for vascular patterning of a myocardial construct
To progress cardiac tissue engineering strategies closer to the clinic, thicker constructs are required to meet the functional need following a cardiac event. Consequently, pre-vascularization of these constructs needs to be investigated to ensure survival and optimal performance of implantable engineered heart tissue. The aim of this research is to investigate the potential of combining extrusion-based bioprinting (EBB) and melt electrowriting for the fabrication of a myocardial construct with a precisely patterned pre-vascular pathway. Gelatin methacryloyl (GelMA) was investigated as a base hydrogel for the respective myocardial and vascular bioinks with collagen, Matrigel and fibrinogen as interpenetrating polymers to support myocardial functionality. Subsequently, extrusion-based printability and viability were investigated to determine the optimal processing parameters for printing into melt electrowritten meshes. Finally, an anatomically inspired vascular pathway was implemented in a dual EBB set-up into melt electrowritten meshes, creating a patterned pre-vascularized myocardial construct. It was determined that a blend of 5% GelMA and 0.8 mg·ml−1 collagen with a low crosslinked density was optimal for myocardial cellular arrangement and alignment within the constructs. For the vascular fraction, the optimized formulation consisted of 5% GelMA, 0.8 mg·ml−1 collagen and 1 mg·ml−1 fibrinogen with a higher crosslinked density, which led to enhanced vascular cell connectivity. Printability assessment confirmed that the optimized bioinks could effectively fill the microfiber mesh while supporting cell viability (∼70%). Finally, the two bioinks were applied using a dual EBB system for the fabrication of a pre-vascular pathway with the shape of a left anterior descending artery within a myocardial construct, whereby the distinct cell populations could be visualized in their respective patterns up to D14. This research investigated the first step towards developing a thick engineered cardiac tissue construct in which a pre-vascularization pathway is fabricated within a myocardial construct.
- 30 June 2023
- Published by IOP Publishing in Biofabrication
- Vol. 15 (3) , 035025
Open AccessConvergence of melt electrowriting and extrusion-based bioprinting for vascular patterning of a myocardial construct
To progress cardiac tissue engineering strategies closer to the clinic, thicker constructs are required to meet the functional need following a cardiac event. Consequently, pre-vascularization of these constructs needs to be investigated to ensure survival and optimal performance of implantable engineered heart tissue. The aim of this research is to investigate the potential of combining extrusion-based bioprinting (EBB) and melt electrowriting for the fabrication of a myocardial construct with a precisely patterned pre-vascular pathway. Gelatin methacryloyl (GelMA) was investigated as a base hydrogel for the respective myocardial and vascular bioinks with collagen, Matrigel and fibrinogen as interpenetrating polymers to support myocardial functionality. Subsequently, extrusion-based printability and viability were investigated to determine the optimal processing parameters for printing into melt electrowritten meshes. Finally, an anatomically inspired vascular pathway was implemented in a dual EBB set-up into melt electrowritten meshes, creating a patterned pre-vascularized myocardial construct. It was determined that a blend of 5% GelMA and 0.8 mg·ml−1 collagen with a low crosslinked density was optimal for myocardial cellular arrangement and alignment within the constructs. For the vascular fraction, the optimized formulation consisted of 5% GelMA, 0.8 mg·ml−1 collagen and 1 mg·ml−1 fibrinogen with a higher crosslinked density, which led to enhanced vascular cell connectivity. Printability assessment confirmed that the optimized bioinks could effectively fill the microfiber mesh while supporting cell viability (∼70%). Finally, the two bioinks were applied using a dual EBB system for the fabrication of a pre-vascular pathway with the shape of a left anterior descending artery within a myocardial construct, whereby the distinct cell populations could be visualized in their respective patterns up to D14. This research investigated the first step towards developing a thick engineered cardiac tissue construct in which a pre-vascularization pathway is fabricated within a myocardial construct.
- Open Access
- 27 December 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-18
Small molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes
Background: Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) do not display all hallmarks of mature primary cardiomyocytes, especially the ability to use fatty acids (FA) as an energy source, containing high mitochondrial mass, presenting binucleation and increased DNA content per nuclei (polyploidism), and synchronized electrical conduction. This immaturity represents a bottleneck to their application in (1) disease modelling—as most cardiac (genetic) diseases have a middle-age onset—and (2) clinically relevant models, where integration and functional coupling are key. So far, several methods have been reported to enhance iPSC-CM maturation; however, these protocols are laborious, costly, and not easily scalable. Therefore, we developed a simple, low-cost, and rapid protocol to promote cardiomyocyte maturation using two small molecule activators of the peroxisome proliferator-activated receptor β/δ and gamma coactivator 1-alpha (PPAR/PGC-1α) pathway: asiatic acid (AA) and GW501516 (GW). Methods and Results: Monolayers of iPSC-CMs were incubated with AA or GW every other day for ten days resulting in increased expression of FA metabolism-related genes and markers for mitochondrial activity. AA-treated iPSC-CMs responsiveness to the mitochondrial respiratory chain inhibitors increased and exhibited higher flexibility in substrate utilization. Additionally, structural maturity improved after treatment as demonstrated by an increase in mRNA expression of sarcomeric-related genes and higher nuclear polyploidy in AA-treated samples. Furthermore, treatment led to increased ion channel gene expression and protein levels. Conclusions: Collectively, we developed a fast, easy, and economical method to induce iPSC-CMs maturation via PPAR/PGC-1α activation. Treatment with AA or GW led to increased metabolic, structural, functional, and electrophysiological maturation, evaluated using a multiparametric quality assessment.
- 27 December 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-18
Open AccessSmall molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes
Background: Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) do not display all hallmarks of mature primary cardiomyocytes, especially the ability to use fatty acids (FA) as an energy source, containing high mitochondrial mass, presenting binucleation and increased DNA content per nuclei (polyploidism), and synchronized electrical conduction. This immaturity represents a bottleneck to their application in (1) disease modelling—as most cardiac (genetic) diseases have a middle-age onset—and (2) clinically relevant models, where integration and functional coupling are key. So far, several methods have been reported to enhance iPSC-CM maturation; however, these protocols are laborious, costly, and not easily scalable. Therefore, we developed a simple, low-cost, and rapid protocol to promote cardiomyocyte maturation using two small molecule activators of the peroxisome proliferator-activated receptor β/δ and gamma coactivator 1-alpha (PPAR/PGC-1α) pathway: asiatic acid (AA) and GW501516 (GW). Methods and Results: Monolayers of iPSC-CMs were incubated with AA or GW every other day for ten days resulting in increased expression of FA metabolism-related genes and markers for mitochondrial activity. AA-treated iPSC-CMs responsiveness to the mitochondrial respiratory chain inhibitors increased and exhibited higher flexibility in substrate utilization. Additionally, structural maturity improved after treatment as demonstrated by an increase in mRNA expression of sarcomeric-related genes and higher nuclear polyploidy in AA-treated samples. Furthermore, treatment led to increased ion channel gene expression and protein levels. Conclusions: Collectively, we developed a fast, easy, and economical method to induce iPSC-CMs maturation via PPAR/PGC-1α activation. Treatment with AA or GW led to increased metabolic, structural, functional, and electrophysiological maturation, evaluated using a multiparametric quality assessment.
- Open Access
- 26 August 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (10) , 1040-1051
Metabolic Maturation Increases Susceptibility to Hypoxia-induced Damage in Human iPSC-derived Cardiomyocytes
The development of new cardioprotective approaches using in vivo models of ischemic heart disease remains challenging as differences in cardiac physiology, phenotype, and disease progression between humans and animals influence model validity and prognostic value. Furthermore, economical and ethical considerations have to be taken into account, especially when using large animal models with relevance for conducting preclinical studies. The development of human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) has opened new opportunities for in vitro studies on cardioprotective compounds. However, the immature cellular phenotype of iPSC-CMs remains a roadblock for disease modeling. Here, we show that metabolic maturation renders the susceptibility of iPSC-CMs to hypoxia further toward a clinically representative phenotype. iPSC-CMs cultured in a conventional medium did not show significant cell death after exposure to hypoxia. In contrast, metabolically matured (MM) iPSC-CMs showed inhibited mitochondrial respiration after exposure to hypoxia and increased cell death upon increased durations of hypoxia. Furthermore, we confirmed the applicability of MM iPSC-CMs for in vitro studies of hypoxic damage by validating the known cardioprotective effect of necroptosis inhibitor necrostatin-1. Our results provide important steps to improving and developing valid and predictive human in vitro models of ischemic heart disease.
- 26 August 2022
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 11 (10) , 1040-1051
Open AccessMetabolic Maturation Increases Susceptibility to Hypoxia-induced Damage in Human iPSC-derived Cardiomyocytes
The development of new cardioprotective approaches using in vivo models of ischemic heart disease remains challenging as differences in cardiac physiology, phenotype, and disease progression between humans and animals influence model validity and prognostic value. Furthermore, economical and ethical considerations have to be taken into account, especially when using large animal models with relevance for conducting preclinical studies. The development of human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) has opened new opportunities for in vitro studies on cardioprotective compounds. However, the immature cellular phenotype of iPSC-CMs remains a roadblock for disease modeling. Here, we show that metabolic maturation renders the susceptibility of iPSC-CMs to hypoxia further toward a clinically representative phenotype. iPSC-CMs cultured in a conventional medium did not show significant cell death after exposure to hypoxia. In contrast, metabolically matured (MM) iPSC-CMs showed inhibited mitochondrial respiration after exposure to hypoxia and increased cell death upon increased durations of hypoxia. Furthermore, we confirmed the applicability of MM iPSC-CMs for in vitro studies of hypoxic damage by validating the known cardioprotective effect of necroptosis inhibitor necrostatin-1. Our results provide important steps to improving and developing valid and predictive human in vitro models of ischemic heart disease.